Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: Results from a single center

Annals of the New York Academy of Sciences

Volumn 1108, Issue , 2007, Pages 76-82

  Tarr, Tünde ^a   Gyorfy, Balázs ^a   Szekanecz, Éva ^a   Bhattoa, Harjit Pal ^a   Zeher, Margit ^a   Szegedi, Gyula ^a   Kiss, Emese ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Cancer; Lupus; Lymphoma; Malignancy

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

ADULT; AGED; BLADDER CANCER; BREAST CANCER; BRONCHUS CANCER; CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GASTROINTESTINAL TUMOR; HEMATOLOGIC MALIGNANCY; HUMAN; HUNGARY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MALE; MORBIDITY; MORTALITY; NONHODGKIN LYMPHOMA; OVARY CANCER; PREVALENCE; RETROSPECTIVE STUDY; SKIN CANCER; STANDARDIZATION; SYSTEMIC LUPUS ERYTHEMATOSUS; UTERINE CERVIX CANCER;

EID: 34948884016     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1422.008     Document Type: Conference Paper

References (19)

1. BERNATSKY, S. et al. 2006. Mortality in systemic lupus erythematosus. Arthritis Rheum. 54: 2550-2557.
2. KISS, E. et al. 1999. Systemic lupus erythematosus survival in Hungary. Results from a single centre. Clin. Exp. Rheumatol. 17: 171-177.
3. SZEKANECZ, E. et al. 2006. Malignancies and soluble tumor antigens in rheumatic diseases. Autoimmune Rev. 6: 42-47.
4. MICHELI, A. et al. Cancer prevalence in European registry areas. Ann. Oncol. 13: 840-865.
5. ZINTZARAS, E. et al. 2005. The risk of lymphoma development in autoimmune diseases. Arch. Intern. Med. 165: 2337-2344.
6. BERNATSKY, S. et al. 2005. Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum. 53: 781-784.
7. TAN, E. M. et al. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25: 1271-1277.
8. HOCHBERG, M. 1997. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40: 1725.
9. BRESLOW, N.E. et al. 1987. Statistical Methods in Cancer Research. Vol. II. The Design and Analysis of Cohort Studies. WHO International Agency for Research on Cancer. Lyon. 302-304.
10. BERNATSKY, S. et al. 2006. Malignancy and autoimmunity. Curr. Opin. Rheum. 18: 129-134.
11. BERNATSKY, S. et al. 2005. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 52: 1481-1490.
12. MELLEMKJAER, L. et al. 1997. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum. 40: 761-768.
13. BRÖJENDAL, L. et al. 2002. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand. J. Rheumatol. 31: 66-71.
14. NIVED, O. et al. 2001. Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus 10: 500-504.
15. SULTAN, S. M. et al. 2000. Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology 39: 1147-1152.
16. RAMSEY-GOLDMAN, R. et al. 1998. Increased risk of malignancy in patients with systemic lupus erythematosus. J. Invest. Med. 46: 217-222.
17. CYBER, J. et al. 2001. Systemic lupus erythematosus and the risk of malignancy. Lupus 10: 394-400.
18. SEEDY, A. et al. 2005. Ultraviolet-A1 phototherapy modulates TH1/Th2 and Tc1/Tc2 balance in patients with systemic lupus erythematosus. Rheumatology (Oxf.) 44: 925-931.
19. GLADMAN, D. et al. 1996. The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 39: 363-369.